阿尔伯塔省非空腹残余胆固醇和心血管疾病风险预测:一项前瞻性队列研究

CMAJ open Pub Date : 2023-07-01 DOI:10.9778/cmajo.20210318
Olivia R Weaver, Jacqueline A Krysa, Ming Ye, Jennifer E Vena, Dean T Eurich, Spencer D Proctor
{"title":"阿尔伯塔省非空腹残余胆固醇和心血管疾病风险预测:一项前瞻性队列研究","authors":"Olivia R Weaver,&nbsp;Jacqueline A Krysa,&nbsp;Ming Ye,&nbsp;Jennifer E Vena,&nbsp;Dean T Eurich,&nbsp;Spencer D Proctor","doi":"10.9778/cmajo.20210318","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>European studies have shown that nonfasting remnant cholesterol can be a strong predictor of cardiovascular disease risk and may contribute to identifying residual risk; however, Canadian data are lacking on nonfasting remnant cholesterol. In this study, we aimed to determine the relation between nonfasting remnant cholesterol, low-density lipoprotein (LDL) cholesterol and cardiovascular disease among people in Alberta.</p><p><strong>Methods: </strong>In this retrospective analysis, we used data from Alberta's Tomorrow Project, a large prospective cohort that enrolled Albertans aged 35-69 years (2000-2015). Participants with consent to data linkage, with complete nonfasting lipid data and without existing cardiovascular disease were included. The nonfasting remnant cholesterol and LDL cholesterol relation with a composite cardiovascular disease outcome of major incident cardiovascular diagnoses, ascertained by linking to Alberta Health databases, was determined by multivariable logistic regression, adjusting for age, sex, statin use, comorbidities, and LDL cholesterol or remnant cholesterol.</p><p><strong>Results: </strong>The final sample of 13 988 participants was 69.4% female, and the mean age was 61.8 (standard deviation [SD] 9.7) years. Follow-up time was approximately 15 years. Mean remnant cholesterol was significantly higher among individuals with versus without cardiovascular disease (0.87 [SD 0.40] mmol/L v. 0.78 [SD 0.38] mmol/L, standardized mean difference [SMD] -0.24), and mean LDL cholesterol was significantly lower (2.69 [SD 0.93] mmol/L v. 2.88 [SD 0.84] mmol/L, SMD 0.21). The odds of incident composite cardiovascular disease were significantly increased per mmol/L increase in remnant cholesterol (adjusted odds ratio [OR] 1.48, 95% confidence interval [CI] 1.27-1.73) but significantly decreased per mmol/L increase in LDL cholesterol (adjusted OR 0.73, 95% CI 0.68-0.79).</p><p><strong>Interpretation: </strong>In this large Albertan cohort of predominantly older females, nonfasting remnant cholesterol had a positive relation with cardiovascular disease incidence, whereas LDL cholesterol did not. These findings support the clinical utility of measuring non-fasting remnant cholesterol to detect cardiovascular disease risk.</p>","PeriodicalId":10432,"journal":{"name":"CMAJ open","volume":"11 4","pages":"E645-E653"},"PeriodicalIF":0.0000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2a/57/cmajo.20210318.PMC10374248.pdf","citationCount":"1","resultStr":"{\"title\":\"Nonfasting remnant cholesterol and cardiovascular disease risk prediction in Albertans: a prospective cohort study.\",\"authors\":\"Olivia R Weaver,&nbsp;Jacqueline A Krysa,&nbsp;Ming Ye,&nbsp;Jennifer E Vena,&nbsp;Dean T Eurich,&nbsp;Spencer D Proctor\",\"doi\":\"10.9778/cmajo.20210318\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>European studies have shown that nonfasting remnant cholesterol can be a strong predictor of cardiovascular disease risk and may contribute to identifying residual risk; however, Canadian data are lacking on nonfasting remnant cholesterol. In this study, we aimed to determine the relation between nonfasting remnant cholesterol, low-density lipoprotein (LDL) cholesterol and cardiovascular disease among people in Alberta.</p><p><strong>Methods: </strong>In this retrospective analysis, we used data from Alberta's Tomorrow Project, a large prospective cohort that enrolled Albertans aged 35-69 years (2000-2015). Participants with consent to data linkage, with complete nonfasting lipid data and without existing cardiovascular disease were included. The nonfasting remnant cholesterol and LDL cholesterol relation with a composite cardiovascular disease outcome of major incident cardiovascular diagnoses, ascertained by linking to Alberta Health databases, was determined by multivariable logistic regression, adjusting for age, sex, statin use, comorbidities, and LDL cholesterol or remnant cholesterol.</p><p><strong>Results: </strong>The final sample of 13 988 participants was 69.4% female, and the mean age was 61.8 (standard deviation [SD] 9.7) years. Follow-up time was approximately 15 years. Mean remnant cholesterol was significantly higher among individuals with versus without cardiovascular disease (0.87 [SD 0.40] mmol/L v. 0.78 [SD 0.38] mmol/L, standardized mean difference [SMD] -0.24), and mean LDL cholesterol was significantly lower (2.69 [SD 0.93] mmol/L v. 2.88 [SD 0.84] mmol/L, SMD 0.21). The odds of incident composite cardiovascular disease were significantly increased per mmol/L increase in remnant cholesterol (adjusted odds ratio [OR] 1.48, 95% confidence interval [CI] 1.27-1.73) but significantly decreased per mmol/L increase in LDL cholesterol (adjusted OR 0.73, 95% CI 0.68-0.79).</p><p><strong>Interpretation: </strong>In this large Albertan cohort of predominantly older females, nonfasting remnant cholesterol had a positive relation with cardiovascular disease incidence, whereas LDL cholesterol did not. These findings support the clinical utility of measuring non-fasting remnant cholesterol to detect cardiovascular disease risk.</p>\",\"PeriodicalId\":10432,\"journal\":{\"name\":\"CMAJ open\",\"volume\":\"11 4\",\"pages\":\"E645-E653\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2a/57/cmajo.20210318.PMC10374248.pdf\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"CMAJ open\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.9778/cmajo.20210318\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"CMAJ open","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.9778/cmajo.20210318","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

摘要

背景:欧洲研究表明,非空腹残余胆固醇可以是心血管疾病风险的一个强有力的预测因子,并可能有助于确定残余风险;然而,加拿大缺乏关于非空腹残余胆固醇的数据。在这项研究中,我们旨在确定阿尔伯塔省人群中非空腹残余胆固醇、低密度脂蛋白(LDL)胆固醇与心血管疾病之间的关系。方法:在这项回顾性分析中,我们使用了来自阿尔伯塔省明天项目的数据,这是一个大型前瞻性队列,招募了年龄在35-69岁之间的阿尔伯塔人(2000-2015)。同意数据链接、具有完整的非空腹血脂数据且无现有心血管疾病的参与者被纳入。非空腹残余胆固醇和低密度脂蛋白胆固醇与主要心血管事件诊断的复合心血管疾病结局的关系,通过连接Alberta Health数据库确定,通过多变量logistic回归确定,调整年龄、性别、他汀类药物使用、合并症、低密度脂蛋白胆固醇或残余胆固醇。结果:最终纳入13988名参与者,女性占69.4%,平均年龄为61.8岁(标准差[SD] 9.7)岁。随访时间约为15年。心血管疾病患者的平均残余胆固醇水平显著高于无心血管疾病患者(0.87 [SD 0.40] mmol/L vs . 0.78 [SD 0.38] mmol/L,标准化平均差值[SMD] -0.24),平均LDL胆固醇水平显著低于无心血管疾病患者(2.69 [SD 0.93] mmol/L vs . 2.88 [SD 0.84] mmol/L, SMD 0.21)。残余胆固醇每增加mmol/L(校正优势比[OR] 1.48, 95%可信区间[CI] 1.27-1.73),复合心血管疾病的发生率显著增加,但LDL胆固醇每增加mmol/L发生率显著降低(校正优势比[OR] 0.73, 95%可信区间[CI] 0.68-0.79)。解释:在这个以老年女性为主的大型阿尔伯塔队列中,非空腹残余胆固醇与心血管疾病发病率呈正相关,而低密度脂蛋白胆固醇则没有。这些发现支持了测量非空腹残余胆固醇来检测心血管疾病风险的临床应用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Nonfasting remnant cholesterol and cardiovascular disease risk prediction in Albertans: a prospective cohort study.

Nonfasting remnant cholesterol and cardiovascular disease risk prediction in Albertans: a prospective cohort study.

Nonfasting remnant cholesterol and cardiovascular disease risk prediction in Albertans: a prospective cohort study.

Nonfasting remnant cholesterol and cardiovascular disease risk prediction in Albertans: a prospective cohort study.

Background: European studies have shown that nonfasting remnant cholesterol can be a strong predictor of cardiovascular disease risk and may contribute to identifying residual risk; however, Canadian data are lacking on nonfasting remnant cholesterol. In this study, we aimed to determine the relation between nonfasting remnant cholesterol, low-density lipoprotein (LDL) cholesterol and cardiovascular disease among people in Alberta.

Methods: In this retrospective analysis, we used data from Alberta's Tomorrow Project, a large prospective cohort that enrolled Albertans aged 35-69 years (2000-2015). Participants with consent to data linkage, with complete nonfasting lipid data and without existing cardiovascular disease were included. The nonfasting remnant cholesterol and LDL cholesterol relation with a composite cardiovascular disease outcome of major incident cardiovascular diagnoses, ascertained by linking to Alberta Health databases, was determined by multivariable logistic regression, adjusting for age, sex, statin use, comorbidities, and LDL cholesterol or remnant cholesterol.

Results: The final sample of 13 988 participants was 69.4% female, and the mean age was 61.8 (standard deviation [SD] 9.7) years. Follow-up time was approximately 15 years. Mean remnant cholesterol was significantly higher among individuals with versus without cardiovascular disease (0.87 [SD 0.40] mmol/L v. 0.78 [SD 0.38] mmol/L, standardized mean difference [SMD] -0.24), and mean LDL cholesterol was significantly lower (2.69 [SD 0.93] mmol/L v. 2.88 [SD 0.84] mmol/L, SMD 0.21). The odds of incident composite cardiovascular disease were significantly increased per mmol/L increase in remnant cholesterol (adjusted odds ratio [OR] 1.48, 95% confidence interval [CI] 1.27-1.73) but significantly decreased per mmol/L increase in LDL cholesterol (adjusted OR 0.73, 95% CI 0.68-0.79).

Interpretation: In this large Albertan cohort of predominantly older females, nonfasting remnant cholesterol had a positive relation with cardiovascular disease incidence, whereas LDL cholesterol did not. These findings support the clinical utility of measuring non-fasting remnant cholesterol to detect cardiovascular disease risk.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信